R
R.A. Sharma
Researcher at Leicester Royal Infirmary
Publications - 19
Citations - 2175
R.A. Sharma is an academic researcher from Leicester Royal Infirmary. The author has contributed to research in topics: Cancer & Clinical trial. The author has an hindex of 11, co-authored 17 publications receiving 2015 citations.
Papers
More filters
Journal ArticleDOI
Curcumin: The story so far
TL;DR: Sufficient data currently exist to advocate phase II clinical evaluation of oral curcumin in patients with invasive malignancy or pre-invasive lesions of the gastrointestinal tract, particularly the colon and rectum.
Journal ArticleDOI
Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies.
S.K. Pathak,S.K. Pathak,R.A. Sharma,William P. Steward,J.K. Mellon,T.R.L. Griffiths,Andreas J. Gescher +6 more
TL;DR: A greater understanding of the molecular events associated with oxidative stress will enhance the development of biomarkers for clinical trials and should result in better strategies for the chemoprevention of prostate cancer.
Journal ArticleDOI
Biological Relevance of Adduct Detection to the Chemoprevention of Cancer
R.A. Sharma,Peter B. Farmer +1 more
TL;DR: The potential efficacy of DNA adducts as biomarkers of carcinogenic and chemoprevention is discussed using criteria defined for phases of biomarker development and the sensitivity of adduct detection in histologically normal tissue offers opportunities for the early detection of carcinogenesis.
Journal ArticleDOI
Angiogenesis as a biomarker and target in cancer chemoprevention.
TL;DR: In this article, the authors used angiogenesis as a biomarker for the effectiveness of chemopreventive intervention in early stages of carcinogenesis and showed that it can be detected in inflammatory and infectious diseases that increase the risk of developing cancer.
Journal ArticleDOI
Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents.
TL;DR: In this paper, the authors use preneoplastic biomarkers to identify the stages of colorectal carcinogenesis and/or mechanisms of action of the agent under investigation.